Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines.


Journal

NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863

Informations de publication

Date de publication:
18 Feb 2022
Historique:
received: 23 12 2021
accepted: 31 01 2022
entrez: 19 2 2022
pubmed: 20 2 2022
medline: 20 2 2022
Statut: epublish

Résumé

SARS-CoV-2 neutralizing antibodies have been suggested to reflect the efficacy of COVID-19 vaccines. This study reports the direct comparison of the SARS-CoV-2 neutralizing antibody response elicited by a protein- (NVX-CoV2373), an mRNA- (Comirnaty), and a vector-based (Vaxzevria) COVID-19 vaccine, calibrated against the WHO international SARS-CoV-2 antibody standard, and further supports the use of neutralizing antibody levels as a correlate of protection.

Identifiants

pubmed: 35181655
doi: 10.1038/s41541-022-00455-3
pii: 10.1038/s41541-022-00455-3
pmc: PMC8857217
doi:

Types de publication

Journal Article

Langues

eng

Pagination

22

Informations de copyright

© 2022. The Author(s).

Références

Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Vaccine. 2022 Jan 21;40(2):306-315
pubmed: 34933765
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
EBioMedicine. 2021 Aug;70:103539
pubmed: 34391087
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Infect Dis. 2021 Mar 16;:
pubmed: 33725725
J Infect Dis. 2020 Nov 13;222(12):1960-1964
pubmed: 32941626
Nat Med. 2021 Jul;27(7):1147-1148
pubmed: 34239135
N Engl J Med. 2021 Sep 23;385(13):1172-1183
pubmed: 34192426
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Dec 16;385(25):2348-2360
pubmed: 34587382
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576

Auteurs

Michael Karbiener (M)

Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria.

Maria R Farcet (MR)

Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria.

Andreas Zollner (A)

Christian Doppler Laboratory for Mucosal Immunology, Johannes Kepler University Linz, Linz, Austria.
Department of Medicine, Division of Internal Medicine 1 (Gastroenterology and Hepatology, Endocrinology and Metabolism), Medical University of Innsbruck, Innsbruck, Austria.

Taisei Masuda (T)

Japan Development, Global Vaccine Business Unit, Takeda Pharmaceutical Company Limited, Osaka, Japan.

Mitsuhiro Mori (M)

Japan Development, Global Vaccine Business Unit, Takeda Pharmaceutical Company Limited, Osaka, Japan.

Alexander R Moschen (AR)

Christian Doppler Laboratory for Mucosal Immunology, Johannes Kepler University Linz, Linz, Austria.
Department of Internal Medicine 2 (Gastroenterology and Hepatology, Endocrinology and Metabolism, Nephrology, Rheumatology), Johannes Kepler University Linz, Linz, Austria.

Thomas R Kreil (TR)

Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria. thomas.kreil@takeda.com.

Classifications MeSH